Latest On Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-08-01 06:00 EST | Dividend | A dividend of $0.46 has been announced on Mar 27, 2023. It will be paid Aug 24, 2023 with an ex-dividend date of Aug 1, 2023. | Neutral |  |
| 2023-05-09 21:25 EST | News | Fosun Pharmaceutical, CanSino Take Different Paths As Covid Lift Fade | N/A | |
| 2023-04-05 00:20 EST | News | Innovative Drugs Soothe Fosun Pharma From Pain Of Fading Covid Vaccine | N/A | |
| 2023-01-11 17:24 EST | News | Syneos, Fosun Pharma team up to launch lung cancer drug serplulimab in US | N/A | |
| 2022-12-23 17:49 EST | News | BioNTech, Fosun Omicron-adapted booster gets approval in Hong Kong for aged 12 and above | N/A | |
| 2022-12-22 07:19 EST | News | BioNTech, Fosun provide mRNA COVID vaccines to German expatriates in China | N/A | |
| 2022-11-23 23:22 EST | News | Sirona, Wanbang expand collaboration on TFC-039 for use in human health | N/A | |
| 2022-11-15 11:57 EST | News | Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely | N/A | |
| 2022-11-04 12:24 EST | News | BioNTech rises as China agrees to offer COVID shot to expats | N/A | |
| 2022-06-09 06:00 EST | Dividend | A dividend of $0.66 has been announced on Mar 23, 2022. It will be paid Jul 4, 2022 with an ex-dividend date of Jun 9, 2022. | Neutral | |
| 2022-03-29 17:08 EST | News | Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins | N/A | |
| 2021-08-24 14:28 EST | News | Shanghai Fosun Pharmaceutical reports 1H results | N/A | |
| 2021-07-22 13:15 EST | News | Kite joint venture gains first CAR T-cell therapy approval in China | N/A | |
| 2021-07-22 13:13 EST | News | BioNTech, Fosun Pharma COVID-19 shot cleared by expert panel in China: Caixing | N/A | |
| 2021-07-08 06:03 EST | Dividend | A dividend of $0.52 has been announced on Mar 29, 2021. It will be paid Aug 3, 2021 with an ex-dividend date of Jul 8, 2021. | Neutral | |
| 2021-04-20 16:09 EST | News | China set to approve BioNTech vaccine in June - Bloomberg | N/A | |
| 2021-04-16 23:45 EST | News | China set to approve BioNTech vaccine before July - WSJ | N/A | |
| 2021-03-29 22:15 EST | News | Shanghai Fosun Pharmaceutical reports FY results | N/A | |
| 2020-12-17 10:09 EST | News | BioNTech, Fosun Pharma to supply 100M doses of COVID-19 vaccine to China | N/A | |
| 2020-11-26 22:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 19:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-26 14:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-22 05:59 EST | Dividend | A dividend of $0.43 has been announced on Mar 30, 2020. It will be paid Aug 14, 2020 with an ex-dividend date of Jul 22, 2020. | Neutral | |
| 2020-07-09 11:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 02:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 02:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 22:59 EST | Financials | Company financials have been released. | Neutral | |
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF):
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China. The company is a subsidiary of Shanghai Fosun High Technology (Group) Co., Ltd.
General
- Name Shanghai Fosun Pharmaceutical (Group) Co., Ltd
- Symbol SFOSF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 31,370
- Fiscal Year EndDecember
- Web URLhttp://www.fosunpharma.com
View More
Valuation
- Trailing PE 26.2
- Forward PE 14.79
- Price/Sales (Trailing 12 Mt.) 2.5
- Price/Book (Most Recent Quarter) 2.23
- Enterprise Value Revenue 0.58
- Enterprise Value EBITDA 2.94
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 13%
- Return on Assets 2%
- Return on Equity 10%
- Earnings Per Share $0.17
- Revenue Per Share $0
- Gross Profit 17.03 billion
- Quarterly Earnings Growth 14.5%
View More
ESG Rating
Highlights
- Market Capitalization 14.82 billion
- Book Value Per Share $1.63
View More
Share Statistics
- Shares Outstanding 551.94 million
- Shares Float 1.55 billion
- % Held by Insiders 6%
- % Held by Institutions 47.57%
View More
Technicals
- Beta 0.65
- 52 Week High $5.51
- 52 Week Low $2.39
- 50 Day Moving Average 4.73
- 200 Day Moving Average 4.71
View More
Dividends
- Forward Annual Dividend Rate $0.06
- Forward Annual Dividend Yield 1.25%
- Payout Ratio 14%
- Dividend Date N/A
- ExDividend Date 2020-07-21
- Dividend Per Share $0.06
- Dividend Yield 0%
View More
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) Dividend Calendar:
Shanghai Fosun Pharmaceutical (Group) Co., Ltd pays out 14% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-10-29 | $8.07 billion | $0.30 | $0.31 | -3.23% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.04 | $0.36 | -87.72% |
| 2020-03-31 | 2020-06-30 | $5.88 billion | $0.06 | $0.21 | -70.71% |
| 2019-12-31 | 2020-03-31 | $7.36 billion | $0.03 | $0.63 | -94.84% |
| 2019-09-30 | 2019-12-31 | $7.05 billion | $0.07 | $0.28 | -75.25% |
| 2019-06-30 | 2019-09-30 | $7.44 billion | $0.03 | $0.35 | -91.2% |
| 2019-03-31 | 2019-06-30 | $6.73 billion | $0.05 | $0.33 | -86.33% |
| 2018-12-31 | 2019-03-31 | $6.78 billion | $0.04 | $0.31 | -86.55% |
| 2018-09-30 | 2018-12-31 | $6.28 billion | $0.03 | $0.36 | -90.31% |
| 2018-06-30 | 2018-09-30 | $6.14 billion | $0.03 | $0.33 | -91.18% |
| 2018-03-31 | 2018-06-30 | $54.01 million | $0.05 | $0.33 | -84.15% |
| 2017-12-31 | 2018-03-31 | $5.57 billion | $0.04 | $0.32 | -86.06% |
| 2017-09-30 | 2017-12-31 | $4.61 billion | $0.04 | $0.32 | -86.5% |
| 2017-06-30 | 2017-09-30 | $3.45 billion | $0.04 | $0.40 | -89.1% |
| 2017-03-31 | 2017-06-30 | $3.88 billion | $0.06 | $0.31 | -82.23% |
| 2016-12-31 | 2017-03-31 | $3.99 billion | $0.05 | $0.29 | -84.48% |
| 2016-09-30 | 2016-12-31 | $0.04 | $0.29 | -87.03% | |
| 2016-06-30 | 2016-09-30 | $0.04 | $0.32 | -86.41% | |
| 2016-03-31 | 2016-06-30 | $0.06 | |||
| 2015-12-31 | 2016-03-31 | $0.04 | $0.22 | -81% | |
| 2015-09-30 | 2015-12-31 | $0.04 | |||
| 2015-06-30 | 2015-09-30 | $0.04 | $0.21 | -81.29% | |
| 2015-03-31 | 2015-06-30 | $0.05 | |||
| 2014-12-31 | 2015-03-31 | $0.04 | |||
| 2014-09-30 | 2014-12-31 | $0.04 | |||
| 2014-06-30 | 2014-09-30 | $0.04 | |||
| 2014-03-31 | 2014-06-30 | $0.04 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.03 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.05 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.02 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.02 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.03 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.04 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.03 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.03 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.03 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.01 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.02 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.05 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.02 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.01 | $0.00 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 673.28 million | N/A | 492.63 million | 751.37 million | 440.65 million |
| Income Before Tax | 1.06 billion | N/A | 769.36 million | 1.57 billion | 762.5 million |
| Selling General Administrative | 3.07 billion | N/A | 2.27 billion | 3.23 billion | 3.09 billion |
| Gross Profit | 4.54 billion | N/A | 3.24 billion | 4.35 billion | 4.12 billion |
| Ebit | 1.27 billion | N/A | 903.96 million | 1.99 billion | 547.63 million |
| Operating Income | 817.31 million | N/A | 509.21 million | 415 million | 547.63 million |
| Income Tax Expense | 218.29 million | 271.21 million | N/A | 279.18 million | 126.53 million |
| Total Revenue | 8.07 billion | N/A | 5.88 billion | 7.36 billion | 7.05 billion |
| Cost of Revenue | 3.54 billion | N/A | 2.64 billion | 3.01 billion | 2.94 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 214.87 million |
| Net Income From Continuing Operations | 840.28 million | N/A | 648.49 million | 1.29 billion | 635.97 million |
| Net Income Applicable to Common Shares | 764.27 million | 1.14 billion | N/A | 1.26 billion | 547.58 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -1.2 billion | 2.39 billion | -351.68 million |
| Change to Liabilities | -820.85 million | 820.85 million | N/A | 873.88 million | -253.07 million |
| Total Cash Flow from Investing Activities | -1.21 billion | -1.17 billion | N/A | 2.39 billion | -1.48 billion |
| Net Borrowings | 1.62 billion | 414.94 million | N/A | -4.21 billion | 1.45 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 3.16 billion |
| Change to Operating Activities | N/A | 112.8 million | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | -161.15 million | -1.37 billion | 2.6 billion |
| Total Cash from Operating Activities | 991.84 million | 1.08 billion | N/A | 894.06 million | 878.17 million |
| Depreciation | N/A | N/A | N/A | N/A | -701.15 million |
| Other Cash Flow from Investing Activities | -321.76 million | 47.85 million | N/A | 72.14 million | 257.93 million |
| Change to Inventory | N/A | N/A | N/A | N/A | 362.84 million |
| Change to Account Receivables | N/A | N/A | N/A | N/A | 496.14 million |
| Other Cash Flow from Financing Activities | -1.37 billion | -125.62 million | N/A | -95.88 million | 2.79 billion |
| Change to Net Income | 478.68 million | -544.24 million | N/A | -1.39 billion | 464.93 million |
| Capital Expenditures | N/A | N/A | 1.03 billion | 1.1 billion | 824.03 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 41.06 billion | N/A | 38 billion | 36.92 billion | 40.62 billion |
| Total Stockholder Equity | 33.08 billion | N/A | 32.73 billion | 31.89 billion | 30.63 billion |
| Other Current Liabilities | 4.95 billion | N/A | 2.13 billion | 3.31 billion | 4.8 billion |
| Total Assets | 80.55 billion | N/A | 77.59 billion | 76.12 billion | 78.57 billion |
| Common Stock | 2.56 billion | 2.56 billion | N/A | 2.56 billion | 2.56 billion |
| Other Current Assets | 633.15 million | N/A | 637.21 million | 599.49 million | 2.13 billion |
| Retained Earnings | 16.53 billion | 18.26 billion | 15.6 billion | 15.13 billion | 16.39 billion |
| Other Liabilities | 6.18 billion | 6.45 billion | N/A | 6.49 billion | 6.39 billion |
| Other Assets | 4.55 billion | 5.1 billion | N/A | 4.68 billion | 3.91 billion |
| Cash | 9.05 billion | N/A | 9.76 billion | 9.53 billion | 10.31 billion |
| Total Current Liabilities | 21.94 billion | N/A | 17.33 billion | 17.43 billion | 19.33 billion |
| Other Stockholder Equity | -419.24 million | -414.84 million | N/A | -467.99 million | 11.68 billion |
| Property, Plant & Equipment | 12.21 billion | 11.54 billion | N/A | 11.09 billion | 10.67 billion |
| Total Current Assets | 22.12 billion | N/A | 20.93 billion | 20.4 billion | 23.41 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 23.52 billion |
| Net Tangible Assets | 15.6 billion | 16.11 billion | N/A | 14.96 billion | 13.57 billion |
| Short Term Investments | 1.02 billion | N/A | 334.85 million | 456.65 million | N/A |
| Long Term Debt | 12.65 billion | N/A | 13.77 billion | 12.58 billion | 14.6 billion |
| Inventory | 4.72 billion | N/A | 4.15 billion | 3.94 billion | 3.86 billion |
| Accounts Payable | 2.87 billion | N/A | 2.49 billion | 2.4 billion | 2.5 billion |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) Chart:
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) News:
Below you will find a list of latest news for Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SFOSF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|